专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

WO2016166373A1 A NOVEL GENE IN NEURODEGENERATIVE DISEASE 审中-公开
标题翻译：神经病变疾病中的新基因
公开(公告)号：WO2016166373A1
公开(公告)日：2016-10-20
申请号：PCT/EP2016/058558
申请日：2016-04-18
申请人： VIB VZW , UNIVERSITEIT ANTWERPEN , KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D
发明人： VAN BROECKHOVEN, Christine , THEUNS, Jessie , VERSTRAETEN, Aline , HEEMAN, Bavo , VANGHELUWE, Peter
IPC分类号： C12Q1/68 , G01N33/68
CPC分类号： C12Q1/6883 , A61K38/46 , C12Q1/6897 , C12Q2600/156 , C12Q2600/158 , C12Y306/03014 , G01N33/6896 , G01N2333/914 , G01N2500/10 , G01N2800/2835
摘要： The present application relates to the field of neurodegenerative diseases, particularly Parkinson's disease (PD), most particularly early-onset PD. Using whole genome sequencing in familial early-onset PD,a novel recessive gene could be identified: ATP10Bencoding a lysosomal phosphatidylcholine (PC) lipid flippase. Determining expression of this gene, or the presence of mutations in this gene, may be used in diagnosis of neurodegenerative disease. Furthermore, restoring or increasing expression levels or function of ATP10B is envisaged as therapy.
摘要翻译：本申请涉及神经变性疾病领域，特别是帕金森病（PD），最特别是早发性PD。在家族性早发性PD中使用全基因组测序，可以鉴定出新的隐性基因：ATP10B编码溶酶体磷脂酰胆碱（PC）脂质翻转酶。确定该基因的表达或该基因中突变的存在可用于诊断神经变性疾病。此外，恢复或增加ATP10B的表达水平或功能被设想为治疗。

12. 发明申请

WO2015183995A3 THERAPEUTIC COMPOSITIONS INCLUDING FRATAXIN, LACTOFERRIN, AND MITOCHONDRIAL ENERGY GENERATING ENZYMES, AND USES THEREOF 审中-公开
标题翻译：包括FRATAXIN，LACTOFERRIN和MITOCHENDRIAL ENERGY GENERATING ENZYMES的治疗组合物及其用途
公开(公告)号：WO2015183995A3
公开(公告)日：2016-01-21
申请号：PCT/US2015032728
申请日：2015-05-27
申请人： STEALTH PEPTIDES INT INC , WILSON D TRAVIS
发明人： WILSON D TRAVIS
IPC分类号： A61K38/07 , A61K31/353
CPC分类号： A61K38/10 , A61K38/05 , A61K38/06 , A61K38/07 , A61K38/08 , A61K38/13 , A61K38/1709 , A61K38/40 , A61K38/44 , A61K38/443 , A61K38/45 , A61K38/46 , A61K38/51 , A61K38/53 , A61K47/48315 , A61K47/645 , C07K5/06078 , C07K5/06095 , C07K5/06156 , C07K5/0812 , C07K5/0815 , C07K5/0817 , C07K5/0821 , C07K5/1016 , C07K5/1021 , C12Y101/01037 , C12Y101/01042 , C12Y102/04002 , C12Y103/05001 , C12Y106/05003 , C12Y109/03001 , C12Y110/02002 , C12Y203/03001 , C12Y306/03014 , C12Y402/01002 , C12Y402/01003 , C12Y602/01004 , C12Y604/01001
摘要： Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of a therapeutic biological molecule, and/or naturally or artificially occurring derivatives, analogues, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide). The present technology provides compositions related to aromatic-cationic peptides linked to a therapeutic biological molecule and uses of the same. In some embodiments, the aromatic-cationic peptide comprises 2',6'-dimethyl-Tyr-D-Arg-Phe-Lys-NH2, Phe-D-Arg-Phe-Lys-NH2, or D-Arg-2',6'-Dmt-Lys-Phe-NH2.
摘要翻译：本文公开了用于治疗和/或预防疾病或病症的方法和组合物，包括施用治疗性生物分子，和/或天然或人造出的衍生物，类似物或其药学上可接受的盐，单独或与一种或多种活性剂（例如，芳族 - 阳离子肽）。本技术提供了与治疗性生物分子连接的芳香族 - 阳离子肽相关的组合物及其用途。在一些实施方案中，芳族阳离子肽包含2'，6'-二甲基-Tyr-D-Arg-Phe-Lys-NH 2，Phe-D-Arg-Phe-Lys-NH 2或D-Arg-2' 6'-DMT-赖氨酸的Phe-NH 2。

13. 发明申请

WO2015183995A2 THERAPEUTIC COMPOSITIONS INCLUDING FRATAXIN, LACTOFERRIN, AND MITOCHONDRIAL ENERGY GENERATING ENZYMES, AND USES THEREOF 审中-公开
标题翻译：包括FRATAXIN，LACTOFERRIN和MITOCHENDRIAL ENERGY GENERATING ENZYMES的治疗组合物及其用途
公开(公告)号：WO2015183995A2
公开(公告)日：2015-12-03
申请号：PCT/US2015/032728
申请日：2015-05-27
申请人： STEALTH PEPTIDES INTERNATIONAL, INC. , WILSON, D. Travis
发明人： WILSON, D. Travis
IPC分类号： A61K38/07 , C07K5/10
CPC分类号： A61K38/10 , A61K38/05 , A61K38/06 , A61K38/07 , A61K38/08 , A61K38/13 , A61K38/1709 , A61K38/40 , A61K38/44 , A61K38/443 , A61K38/45 , A61K38/46 , A61K38/51 , A61K38/53 , A61K47/645 , C07K5/06078 , C07K5/06095 , C07K5/06156 , C07K5/0812 , C07K5/0815 , C07K5/0817 , C07K5/0821 , C07K5/1016 , C07K5/1021 , C12Y101/01037 , C12Y101/01042 , C12Y102/04002 , C12Y103/05001 , C12Y106/05003 , C12Y109/03001 , C12Y110/02002 , C12Y203/03001 , C12Y306/03014 , C12Y402/01002 , C12Y402/01003 , C12Y602/01004 , C12Y604/01001
摘要： Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of a therapeutic biological molecule, and/or naturally or artificially occurring derivatives, analogues, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents ( e.g. , an aromatic-cationic peptide). The present technology provides compositions related to aromatic-cationic peptides linked to a therapeutic biological molecule and uses of the same. In some embodiments, the aromatic-cationic peptide comprises 2',6'-dimethyl-Tyr-D-Arg-Phe-Lys-NH 2 , Phe-D-Arg-Phe-Lys-NH 2 , or D-Arg-2',6'-Dmt-Lys-Phe-NH 2 .
摘要翻译：本文公开了用于治疗和/或预防疾病或病症的方法和组合物，包括施用治疗性生物分子，和/或天然或人造出的衍生物，类似物或其药学上可接受的盐，单独或与一种或多种活性剂（例如，芳族 - 阳离子肽）。本技术提供了与治疗性生物分子连接的芳香族 - 阳离子肽相关的组合物及其用途。在一些实施方案中，芳族阳离子肽包含2'，6'-二甲基-Tyr-D-Arg-Phe-Lys-NH 2，Phe-D-Arg-Phe-Lys-NH 2或D-Arg-2' 6'-DMT-赖氨酸的Phe-NH 2。

14. 发明申请

WO2014165622A1 ENHANCED YEAST FERMENTATION PLATFORM USING YEAST LACKING MITOCHONDRIAL DNA AND CONTAINING GROWTH IMPROVING MUTATIONS 审中-公开
标题翻译：使用YEAST LACKING MITOCHONDRIAL DNA并增加增长的增强型YEAST发酵平台
公开(公告)号：WO2014165622A1
公开(公告)日：2014-10-09
申请号：PCT/US2014/032720
申请日：2014-04-02
申请人： UNIVERSITY OF WYOMING
发明人： THORSNESS, Peter E. , SMITH, Christopher P.
IPC分类号： C12N1/19
CPC分类号： C12N15/81 , C12N9/0083 , C12N9/14 , C12P7/06 , C12Y114/99001 , C12Y306/03014 , Y02E50/17
摘要： Methods for enhanced yeast fermentation of plant material through the genetic modification of non-respiring yeast are provided including the introduction of a dominant mitochondrial ATP synthase gene mutation into a non-respiring yeast that entirely lacks mitochondrial DNA and transgenic yeast for the enhanced yeast fermentation of plant material lacking mitochondrial DNA while having a dominant mitochondrial ATP synthase gene mutation in the nuclear genome. Methods further include the introduction of a mitochondrial genome into a non-respiring yeast lacking the COX1, COX2, COX3, or COB gene as well as transgenic yeast having a mitochondrial genome lacking the COX1, COX2, COX3, or COB gene. Additional methods include the creation of a disrupted copy of the CATS nuclear gene in a non- respiring yeast as well as transgenic yeast having a disrupted copy of the CATS nuclear gene are also disclosed.
摘要翻译：提供通过非呼吸酵母的遗传修饰增强植物材料酵母发酵的方法，包括将显着的线粒体ATP合酶基因突变引入到完全缺乏线粒体DNA的非呼吸酵母中，并且用于增强酵母发酵的转基因酵母植物材料缺乏线粒体DNA，同时在核基因组中具有显着的线粒体ATP合酶基因突变。方法还包括将线粒体基因组导入缺乏COX1，COX2，COX3或COB基因的非呼吸性酵母以及缺乏COX1，COX2，COX3或COB基因的线粒体基因的转基因酵母。还公开了另外的方法包括在非呼吸酵母中产生CATS核基因的破坏拷贝以及具有CATS核基因的破坏拷贝的转基因酵母。

15. 发明申请

WO2008131431A2 MODULATION OF BLOOD BRAIN BARRIER PROTEIN EXPRESSION 审中-公开
标题翻译：血脑屏障蛋白表达调控
公开(公告)号：WO2008131431A2
公开(公告)日：2008-10-30
申请号：PCT/US2008/061316
申请日：2008-04-23
申请人： ST. LOUIS UNIVERSITY
IPC分类号： A61K48/00
CPC分类号： C07K14/705 , C12N15/111 , C12N15/113 , C12N15/1137 , C12N15/1138 , C12N2310/11 , C12N2310/14 , C12N2320/31 , C12Y306/03014
摘要： There are disclosed agents that inhibit Blood Brain Barrier Proteins (BBBP). Such agents are useful in controlling agents entering and exiting the CNS. This allows for drugs to be more effective and/or allowing side effects of the drugs to be lowered.
摘要翻译：已经公开了抑制血脑屏障蛋白（BBBP）的药剂。这些试剂可用于控制进入和离开CNS的试剂。这允许药物更有效和/或允许降低药物的副作用。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式